Rising Prevalence of Hunter Syndrome is projected to drive the Demand for Hunter Syndrome Treatment Market

 

According to the article published in NCBI, the estimated incidence of Hunter syndrome in the U.S. is between 0.69 and 1.19 per 100,000 live births. The rise in prevalence of MPS II is due to the change in population demographics, along with other underlying factors such as family history, gender among others. The rise in prevalence of hunter syndrome would rise collaborations between market players. That would lead to an increase in investments and funds being granted by public-private and government organizations. It would also ensure the safe health of the male patients. Hence, it can act as a driving factor for market growth.

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-hunter-syndrome-treatment-market

Data Bridge Market Research analyses that the hunter syndrome treatment market is expected to grow at a CAGR of 8.1% in the forecast period of 2021 to 2028 and is expected to reach USD 1,521.74 million by 2028. The increasing prevalence of MPS II is further creating burden across the world, to overcome this burden various government has taken several steps to aware the people about the disease. National MPS Society is engaged in researching to understand, treat and manage the hunter syndrome. Thus, the government initiatives are increasing disease awareness among people, increasing the market's growth.

Hunter Syndrome Treatment Market

Rising Adoption of Gene Therapy Is Expected To Drive the Market's Growth Rate

Gene therapy is considered to be an effective treatment in MPS II and has led to rising adoption and increasing demand day by day for novel and long-lasting results. The therapy includes the replacement of chromosomes responsible for producing the missing enzyme that could cure hunter syndrome. Due to the rising demand, manufacturers are constantly focused on producing gene therapies and are achieving product approval and marketing authorizations. Currently, many companies are engaged in providing gene therapy services to patients with MPS II. Lifesaving medicines and therapies are in huge demand to provide quality life to patients with rare diseases. These patients largely depend on the gene therapies available to achieve a proper cure. For the manufacturing of gene therapies, synthetic and novel genes are required, which can be achieved by the gene synthesis technique. Thus, this signifies that the rising adoption of gene therapy is a driver for the hunter syndrome treatment market.

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2021 to 2028

Base Year

2020

Historic Years

2019(Customizable to 2013 - 2018)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Severity (Mild to Moderate, Moderate to Severe), Type (Enzyme Replacement Therapy (ERT), Stem Cell Transplant, Surgical Treatment, Others), Complications (Respiratory Disorders, Neurological Disorders, Gastrointestinal Disorders, Cardiovascular, Ophthalmic, Audiologic, Dental, Musculoskeletal, Others), End User (Hospitals, Clinics, Home Healthcare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Market Players Covered

Takeda Pharmaceutical Company Limited (Japan), Medtronic (U.S.), Abbott (U.S.), On-X Life Technologies (a subsidiary of CryoLife Inc.), BD (U.S.), Johnson & Johnson Services, Inc. (U.S.), Stryker (U.S.), Homology Medicines, Inc. (U.S.), UCB S.A. (Belgium), Novartis AG (Switzerland), Inventiva (France), Pfizer Inc. (U.S.), JCR Pharmaceuticals Co., Ltd. (Japan), Sangamo Therapeutics (U.S.), Green Cross Corp. (South Korea), AVROBIO Inc. (U.S.), REGENXBIO Inc. (U.S.), CANbridge Life Sciences Ltd. (China), Denali Therapeutics (U.S.) and Jasper Therapeutics (U.S.)

Data Points Covered in Report

In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Segment Analysis:

Global hunter syndrome treatment market is categorized into five notable segments which are based on severity, type, complications, end user and distribution channel.

  • On the basis of severity, the global hunter syndrome treatment market is segmented into mild to moderate and moderate to severe. In 2021, moderate to severe segment is expected to dominate the market with the market share, growing with the highest CAGR of 8.2%

The moderate to severe segment is expected to dominate the market with the market share

In 2021, moderate to severe segment is expected to dominate the market with the market share, growing with the highest CAGR of 8.2% in the forecast period of 2021 to 2028 due to increase in the cases of prevalence rate of genetic inherited disorders among population across the globe.

  • On the basis of type, the global hunter syndrome treatment market is segmented into enzyme replacement therapy (ERT), stem cell transplant, surgical treatment and others. In 2021, enzyme replacement therapy (ERT) segment is expected to dominate the market with the market share, growing with the highest CAGR of 8.2% in the forecast period of 2021 to 2028 due to rising adoption of gene therapy in the market.
  • On the basis of complications, the global hunter syndrome treatment market is segmented into respiratory disorders, neurological disorders, gastrointestinal disorders, cardiovascular, ophthalmic, audio logic, dental, musculoskeletal and others. In 2021, respiratory disorders segment is expected to dominate the global hunter syndrome treatment market with the market share, growing with the highest CAGR of 8.7% in the forecast period of 2021 to 2028 due to increasing R&D investments by key market players in the market.
  • On the basis of end user, the global hunter syndrome treatment market is segmented into hospitals, clinics, home healthcare and others. In 2021, hospitals segment is expected to dominate the market with the market share, growing with the highest CAGR of 8.0% in the forecast period of 2021 to 2028 due to favorable government initiatives in the market.
  • On the basis of distribution channel, the global hunter syndrome treatment market is segmented into hospital pharmacy, retail pharmacy, online pharmacy and others. In 2021, hospital pharmacy segment is expected to dominate the market with the market share, growing with the highest CAGR of 8.2% in the forecast period of 2021 to 2028 due to novel product launches and approvals in the market.

Major Players

Data Bridge Market Research recognizes the following companies as the major hunter syndrome treatment market players in hunter syndrome treatment market are Takeda Pharmaceutical Company Limited (Japan), Medtronic (U.S.), Abbott (U.S.), On-X Life Technologies (a subsidiary of CryoLife Inc.), BD (U.S.), Johnson & Johnson Services, Inc. (U.S.), Stryker (U.S.), Homology Medicines, Inc. (U.S.), UCB S.A. (Belgium), Novartis AG (Switzerland), Inventiva (France), Pfizer Inc. (U.S.), JCR Pharmaceuticals Co., Ltd. (Japan), Sangamo Therapeutics (U.S.), Green Cross Corp. (South Korea), AVROBIO Inc. (U.S.), REGENXBIO Inc. (U.S.), CANbridge Life Sciences Ltd. (China), Denali Therapeutics (U.S.) and Jasper Therapeutics (U.S..

Hunter Syndrome Treatment Market

Market Development

  • In March 2021, Denali Therapeutics Inc., a biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ETV: IDS (DNL310) for the treatment of patients with Hunter syndrome (MPS II). DNL310, Denali’s lead investigational brain-penetrant enzyme replacement therapy, is under evaluation in a Phase 1/2 study in patients with Hunter syndrome as a potential treatment for both central nervous system (CNS) and peripheral manifestations of the disease.
  • In May 2021, Jasper Therapeutics, Inc., a biotechnology company focused on hematopoietic cell transplant therapies, and Amplitude Healthcare Acquisition Corporation, a special purpose acquisition company (SPAC) sponsored by affiliates of Avego Management, LLC and Metalmark Capital, announced they have entered into a definitive business combination agreement. The companies announced the merger to Create a Publicly Listed Leading Biotechnology Company in Hematopoietic Stem Cell Transplantation.
  • In June 2021, Stryker announced the partnership with Texas Health Hospital Mansfield. Texas Health Hospital has adopted the full suite of Stryker products to support its journey to eliminate harm for healthcare providers and patients in the operating room. This has strengthened the relations between the two, and the company can earn more revenue.
  • In January 2021, Green Cross Corp. announced the marketing and manufacturing approval for Hunterase ICV (intracerebroventricular) Injection 15 mg (generic name: idursulfase-beta (recombinant)) as a treatment for MPS II (Hunter syndrome). This has helped the company develop and commercialize the treatment to fulfill the unmet needs of rare disease patients.
  • In January 2021, Pfizer Inc. announced that during the second half of 2020, it invested a total of USD 120.00 million in four clinical-stage biotech companies as part of the Pfizer Breakthrough Growth Initiative (PBGI). Pfizer is investing a huge amount of around USD 500.00 million in various biotechnology companies. This investment will help Pfizer ensure the continuity of promising clinical development programs for future strategic interests. It helped the company expand its business by entering and innovating new products. 

Regional Analysis

Geographically, the countries covered in the hunter syndrome treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

As per Data Bridge Market Research analysis:

North America is the dominant region in hunter syndrome treatment market during the forecast period

North America dominated the hunter syndrome treatment market owing to the increasing investment in innovative research and development for novel drug products. North America will continue to dominate the hunter syndrome treatment market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period due to rising prevalence of genetic inherited disorders and rising adoption of gene therapy.

Asia-Pacific is estimated to be the fastest-growing region in hunter syndrome treatment market

Asia-Pacific is expected to grow during the forecast period due to the development of healthcare infrastructure and the rising number of generic drug manufacturer in this region. In addition, f increasing investment in innovative research and development for novel treatment product are expected to propel the market's growth rate in this region.

COVID-19 Impact Analysis

The COVID-19 outbreak negatively impacted the global hunter syndrome treatment market. COVID-19 has caused a disruption in the product supply chain. Many actions have been cancelled or stopped due to the present pandemic scenario to lessen the danger of people contracting COVID-19 and to assist the hospital, physician, and over-the-counter care needed to combat the pandemic. To prevent the spread of the disease, lockdown measures in many nations have led to the closure of product providers and a reduction in walk-in clients. This caused a major delay in the medication and drugs delivery. The COVID-19 epidemic has affected the diagnostic industries as well as reduced public mobility. To prevent the spread of the novel coronavirus, a number of diagnostic procedures and non-emergent therapies were suspended.

For more detailed information about the hunter syndrome treatment market report, click here – https://www.databridgemarketresearch.com/reports/global-hunter-syndrome-treatment-market